HSD17B4 and hepatocellular carcinoma: In this study, VK2 directly binds to HSD17B4 to inhibit the proliferation of HCC cells by inhibiting the activation of Akt and MEK/ERK signaling pathways, leading to decreased STAT3 activation (Figure 5).